Current Rheumatology Reports

, Volume 14, Issue 6, pp 509–515 | Cite as

Advances in Therapy for ANCA-Associated Vasculitis

VASCULITIS (LR ESPINOZA, SECTION EDITOR)

Abstract

The anti-neutrophil cytoplasmic antibody-associated vasculitides include granulomatosis with polyangiitis (Wegener’s granulomatosis) and microscopic polyangiitis. The introduction of therapy with cytotoxic agents such as cyclophosphamide transformed these diseases from fatal diagnoses to chronic conditions characterized by cycles of relapse and remission. Modern treatment strategies have focused on minimizing cyclophosphamide exposure or eliminating its use altogether. Two randomized clinical trials have shown that rituximab is not inferior to cyclophosphamide for induction of remission in patients with severe granulomatosis with polyangiitis (Wegener’s) or microscopic polyangiitis. For patients with non-life threatening disease, methotrexate may be used to induce and maintain remission, although some patients may have a higher long-term risk of relapse as a result. For patients with life-threatening disease, plasma exchange may be an effective adjuvant therapy. This article reviews seminal studies from the past decade that have contributed to the current standard of care.

Keywords

Microscopic polyangiitis Wegener’s granulomatosis Granulomatosis with polyangiitis ANCA Cyclophosphamide Therapy ANCA-associated vasculitis Plasma exchange Remission Treatment Biological therapy 

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med. 2004;117(1):39–50.PubMedCrossRefGoogle Scholar
  2. 2.
    Chung SA, Seo P. Microscopic polyangiitis. Rheum Dis Clin North Am. 2010;36(3):545–58.PubMedCrossRefGoogle Scholar
  3. 3.
    Gadola SD, Gross WL. Vasculitis in 2011: The renaissance of granulomatous inflammation in AAV. Nat Rev Rheumatol. 2012;8(2):74–6.PubMedGoogle Scholar
  4. 4.
    Wolff S, Fauci A, Horn R, Dale D. Wegener's granulomatosis. Ann Intern Med. 1974;81:513–25.PubMedGoogle Scholar
  5. 5.
    Wohlwill F. Ueber die nur mikroskopisch erkenbarre form der periarteritis nodosa. Arch Pathol Anat. 1923;246:377–411.CrossRefGoogle Scholar
  6. 6.
    Fauci A, Doppman J, Wolff S. Cyclophosphamide-induced remissions in advanced polyarteritis nodosa. Am J Med. 1978;64:890–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Fauci A, Wolff S. Wegener's granulomatosis: Studies in eighteen patients and a review of the literature. Medicine. 1973;52:53–61.CrossRefGoogle Scholar
  8. 8.
    Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener's granulomatosis: An analysis of 158 patients. Ann Intern Med. 1992;116:488–98.PubMedGoogle Scholar
  9. 9.
    Langford C, Talar-Williams C, Barron K, Sneller M. A staged approach to the treatment of Wegener’s granulomatosis: Induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum. 1999;42(12):2666–73.PubMedCrossRefGoogle Scholar
  10. 10.
    Jayne D. Randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (CYCAZAREM). J Am Soc Nephrol. 1999;10:105A.Google Scholar
  11. 11.
    Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26):2790–803.PubMedCrossRefGoogle Scholar
  12. 12.
    Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial. JAMA. 2010;304(21):2381–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Zahr N, Arnaud L, Marquet P, et al. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum. 2010;62(7):2047–54.PubMedGoogle Scholar
  14. 14.
    Guillevin L, Cordier J, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum. 1997;40(12):2187–98.PubMedCrossRefGoogle Scholar
  15. 15.
    de Groot K, Adu D, Savage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: Meta-analysis and critical review. Nephrol Dial Transplant. 2001;16(10):2018–27.PubMedCrossRefGoogle Scholar
  16. 16.
    De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52(8):2461–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: Long-term follow-up. Ann Rheum Dis. 2012;71(6):955–60.PubMedCrossRefGoogle Scholar
  18. 18.
    de Groot K, Muhler M, Reinhold-Keller E, Paulsen J, Gross W. Induction of remission in Wegener’s granulomatosis with low dose methotrexate. J Rheumatol. 1998;25:492–5.PubMedGoogle Scholar
  19. 19.
    Hoffman GS, Langford CA. Can methotrexate replace cyclophosphamide in the treatment of a subset of Wegener’s granulomatosis and microscopic polyangiitis? Nat Clin Pract Rheumatol. 2006;2(2):70–1.PubMedCrossRefGoogle Scholar
  20. 20.
    Langford C, Fauci A, Talar-Williams C, Sneller M. Treatment of Wegener’s granulomatosis with methotrexate and glucocorticoids: Update on rate of relapse. Arthritis Rheum. 1996;39:S211.Google Scholar
  21. 21.
    •• Faurschou M, Westman K, Rasmussen N, et al. Long-term outcome of a clinical trial comparing methotrexate to cyclophosphamide for remission induction of early systemic ANCA-associated vasculitis. Arthritis Rheum. 2012. It is sobering to realize that a strategy that initially seemed to spare patients from exposure to cyclophosphamide may not work as well as we had hoped. Presumably, in cases where equipoise seems to exist, cyclophosphamide should be chosen over methotrexate as an initial remission induction strategy until the implications of this study are clearer. Google Scholar
  22. 22.
    Villa-Forte A, Clark TM, Gomes M, et al. Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: A 12-year single-practice experience. Medicine (Baltimore). 2007;86(5):269–77.CrossRefGoogle Scholar
  23. 23.
    Pinching A, Rees A, Pussell B, Lockwood C, Mitchison R, Peters D. Relapses in Wegener’s granulomatosis: The role of infection. BMJ. 1980;281:836–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Jennette JC, Falk RJ, Gasim AH. Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis. Curr Opin Nephrol Hypertens. 2011;20(3):263–70.PubMedCrossRefGoogle Scholar
  25. 25.
    Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180–8.PubMedCrossRefGoogle Scholar
  27. 27.
    •• Walsh M, Catapano F, Szpirt W, et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: A meta-analysis. Am J Kidney Dis. 2011;57(4):566–574. This meta-analysis is the closest we have to a definitive statement regarding the utility of plasma exchange for patients with ANCA-associated glomerulonephritis. PubMedCrossRefGoogle Scholar
  28. 28.
    Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med. 2005;352(4):351–61.CrossRefGoogle Scholar
  29. 29.
    de Menthon M, Cohen P, Pagnoux C, et al. Infliximab or rituximab for refractory Wegener’s granulomatosis: Long-term follow up A prospective randomised multicentre study on 17 patients. Clin Exp Rheumatol. 2011;29(1 Suppl 64):S63–71.PubMedGoogle Scholar
  30. 30.
    Booth A, Harper L, Hammad T, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 2004;15(3):717–21.PubMedCrossRefGoogle Scholar
  31. 31.
    Zouboulis C, et al. Adamantiades-behcet's disease: Interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch Dermatol Res. 2000;292:279–84.PubMedCrossRefGoogle Scholar
  32. 32.
    •• Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–220. This article, and the subsequent reference, let to the first drug approved by the United States Food and Drug Administration for the treatment of systemic vasculitis. Reviewing both articles carefully will give you a better sense of the limits of our understanding regarding the use of rituximab for patients with ANCA-associated vasculitis. PubMedCrossRefGoogle Scholar
  33. 33.
    Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32.PubMedCrossRefGoogle Scholar
  34. 34.
    Holle JU, Dubrau C, Herlyn K, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): Comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis. 2012;71(3):327–33.PubMedCrossRefGoogle Scholar
  35. 35.
    •• Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. Arthritis Rheum. 2012. Epub ahead of print. The key unanswered question regarding rituximab is how to use the drug for remission maintenance. This study describes the outcomes associated with one possible re-treatment strategy. Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Johns Hopkins University School of MedicineBaltimoreUSA
  2. 2.The Johns Hopkins Vasculitis CenterBaltimoreUSA

Personalised recommendations